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Pharmaceutics
diabetes in 2010 is 6.4%, affecting 285 million adults and 
may be around 7.7% by 2030 affecting 439 million adults. 
There may be a 69% increase in number of diabetics in 
developing countries and about 20% increase in developed 
countries by 2030.[1]
Diabetes is a metabolic disease occurring when the pancreas 
does not produce enough insulin or when the produced 
insulin cannot be effectively used by the body leading to 
serious damage to the body's systems.[2]
Thiazolidinediones (TZDs), a class of oral hypoglycemic 
agent reverses few metabolic processes which are 
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the three cyclodextrins were classified as AL‑type, indicating the formation of 1:1 stoichiometric inclusion complexes. 
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responsible for development of insulin resistance leading 
to type 2 diabetes mellitus. TZDs act through nuclear 
hormone, peroxisome proliferator activated receptor‑γ 
(PPARγ) which increases insulin sensitivity by enhancing 
the expression of proteins responsible for modulating 
glucose and lipid metabolism leading to improved insulin 
sensitivity in the liver, muscle and adipose tissue. Members 
of the class TZDs include troglitazone, pioglitazone, 
darglitazone and rosiglitazone.[3,4]
Pioglitazone, a member of the thiazolidinedione group 
of drugs used for the treatment of type 2 diabetes 
mellitus. The solubility of its hydrochloride salt is low 
which may have a negative impact on its dissolution rate, 
leading to subtherapeutic plasma drug levels affecting 
therapeutic action. Methods for increasing the aqueous 
solubility of poor soluble drugs include: Complexation, 
addition of surface active agents, preparation of soluble 
prodrug, cosolvency, salt formation, hydrotropism, crystal 
engineering and addition of ionic liquids. Among these 
approaches, preparation of cyclodextrin (CD) inclusion 
complexes of the drug has proven effective in enhancing 
the solubility of poorly water‑soluble drugs.[5‑7]
CDs are glucopyranose units linked by α‑(1, 4) bonds 
consisting of six to more than 100 glucose units. 
Intramolecular transglycosylation reaction of starch by 
CD glucanotransferase (CGTase) enzyme yields a mixture 
of CDs like α‑, β‑ and γ‑CDs consisting of six, seven or 
eight glucose units, respectively.
CDs form inclusion complexes with a wide range of 
hydrophobic molecules. In solution, the hydrophobic CD 
cavity is occupied by water molecules which are bounded 
by “weak forces” that can be substituted by hydrophobic 
molecules such as drugs to form complexes. Depending 
on the size of the internal cavity, one or two hydrophobic 
molecules can be entrapped by one, two or even three CDs.[8]
In the present research work, inclusion complexes of 
pioglitazone with CDs were prepared by kneading method 
for comparative evaluation of β‑cyclodextrin, its water 
soluble derivative methyl‑β cyclodextrin and γ‑cyclodextrin. 
As per the solubility studies of kneaded complexes, 
M‑βCD was selected for preparation of complexes by 
spray drying method to further enhance the solubility 
of pioglitazone. Further formation of complexes was 
confirmed by solubility studies, in vitro dissolution studies, 
Fourier transformation‑infrared spectroscopy (FTIR), 
scanning electron microscopy (SEM), differential scanning 
calorimetry (DSC) and X‑ray powder diffraction (XRPD) 
studies.
MATERIALS AND METHODS
Pioglitazone HCl was a gift sample from Dr. Reddy’s, γ‑CD 
and M‑βCD were kindly provided by Roquette, France, 
β‑CD was kindly provided by Signet Chemicals, Mumbai. 
All other chemicals and reagents were of analytical grade.
Phase solubility studies
The stability constants for inclusion complex formations 
between pioglitazone and CDs were determined using the 
phase solubility method (Higuchi and Connors).[9] Samples 
were prepared by adding 20 ml of distilled water as a media to 
30 ml screw‑capped bottles containing successively increasing 
concentration of cyclodextrin as follows 0.5, 1, 1.5, 2.5, 5 
and 10 mM. Excess amount of pioglitazone was added to 
each bottle to maintain saturated conditions, in aqueous 
solutions of β‑CD, Mβ‑CD and γ‑CD solutions. Each bottle 
was capped and shaken for 24 h at 25 ± 1°. Aliquots were 
filtered with Whatman filter and complexed pioglitazone was 
analyzed by UV spectrophotometer (270 nm).
The apparent stability constants (KS) were calculated from 
the straight line portion of the phase solubility using the 
following Eqn., Ks = Slope/S0 (1−Slope), where, S0 is the 
solubility of drug at 25° in the absence of CDs and slope 
means the corresponding slope of the phase‑solubility 
diagrams.
The Gibbs free energies of transfer of drug from aqueous 
solution to the cavity of cyclodextrin have been calculated 
from following Eqn., ΔG0 = −2.303RT log [S0/SS], where, 
SS and S0 are the solubility of drug in the presence and 
absence of cyclodextrin, respectively.[10]
Preparation of solid binary systems
The following binary systems of pioglitazone and CDs 
were prepared at 1:1 molar ratio.
Preparation of physical mixture of pioglitazone and 
cyclodextrin
The physical mixture (PM) of pioglitazone and CDs viz., 
β, methyl‑β and γ‑CD in 1:1 molar ratio was prepared by 
mixing individual components that had previously been 
sieved through mesh number 60.[11]
Preparation of inclusion complexes by kneading 
method
Drug and cyclodextrin are weighed in terms of equal 
molar ratios (1:1). This molar ratio was selected after phase Pandit, et al.: Pioglitazone cyclodextrin inclusion complexes
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solubility studies. β‑CD, Mβ‑CD or γ‑CD was wetted 
in a ceramic mortar with 50% ethanol solution until a 
paste was obtained. Required amount of pioglitazone 
was added slowly and kneaded for about 45 min. The 
product was dried at 40° for 24 h. The dry mass so 
obtained was powdered and passed through sieve no. 
60. Prepared complexes were stored in a desiccator for 
further studies.[12]
Preparation of inclusion complexes by spray drying 
method
Drug and CD are weighed in terms of equal molar ratios 
(1:1). This molar ratio was selected after phase solubility 
studies. Drug was dissolved in 25 ml ethanol‑acetone (1:1) 
mixture with constant stirring and added to a solution 
of cyclodextrin (Mβ‑CD) dissolved in 25 ml of same 
solvent mixture. This mixture of solutions was sonicated 
for 15 min and this feed was fed to (Lab Ultima‑222, 
Mumbai) mini spray drier and sprayed into the chamber 
from a nozzle with a diameter 0.7 mm (700 μm) under the 
following conditions: Inlet air temperature of 65°, outlet air 
temperature of 55°, cool temperature of 50°, inlet high of 
75°, outlet high of 60°, feed rate of 3 ml/min, atomization 
air pressure of 2.5 kg/cm2, aspirator speed 30% and 
vacuum in the system of 100 wc/mm. The product thus 
obtained was collected, packed in aluminum foil and stored 
in desiccator for further studies.
Characterization of pioglitazone CD inclusion 
complexes
Solubility studies
Excess of prepared inclusion complexes were dispersed 
in the 20 ml of distilled water in screw‑capped bottles 
to get a supersaturated solution. These bottles were 
shaken continuously for 4 h at ambient temperature until 
equilibrium was attained. Aliquots were filtered with 
Whatman filter and total pioglitazone was analyzed by 
spectrophotometer (270 nm). Solubility studies were also 
performed for pure drug.[10]
In vitro dissolution studies
In vitro dissolution of pure drug and inclusion complexes 
were studied in USP XXIII dissolution apparatus 
(Electrolab) employing a paddle stirrer at 75 rpm and 
using 500 ml of distilled water at 37 ± 0.1° as dissolution 
medium. Complexes equivalent to 15 mg of pioglitazone 
was used in each test. Aliquots of dissolution medium 
(5 ml) were withdrawn at known intervals of time and 
filtered through Whatman filter paper and 1 ml of the 
filtrate was made up to 10 ml with 0.2N HCl in 10 ml 
volumetric flasks. Suitable dilutions were further made 
when required. The absorbance of the samples was read 
at 270 nm against blank. The aliquot withdrawn at each 
time interval was replaced with the same volume of fresh 
dissolution medium. All the experiments were run in 
triplicate.[13]
Fourier transformation‑infrared spectroscopy
Infrared spectra were obtained using Shimadzu Fourier 
transformation‑infrared (FTIR)‑8700 spectrophotometer 
using KBr disks. The samples of pioglitazone, Mβ‑CD, 
physical mixtures of pioglitazone and Mβ‑CD and 
inclusion complexes were previously ground and mixed 
thoroughly with KBr. The KBr disks were prepared by 
compressing the powder. The scanning range was kept 
from 4000 to 450 cm−1.
Scanning electron microscopy studies
The surface morphology of pioglitazone, physical mixtures 
and inclusion complexes was examined by using Scanning 
electron microscopy (SEM). The small amount of powder 
was manually dispersed onto a carbon tab adhered to an 
aluminum stubs. Then these stubs were coated with a thin 
layer of gold by employing POLARON‑E 3000 sputter 
coater. The samples were examined using Joel JSM 840A 
SEM and photographed under various magnifications with 
direct data capture of the images onto a computer.
Differential scanning calorimetry studies
Differential scanning calorimetry of pioglitazone, Mβ‑CD, 
physical mixtures and inclusion complexes were conducted 
using Differential scanning calorimetry (DSC) Q2000 
V24.2 Build 107 instrument. The mass of empty pan and 
reference pan were taken into account for calculation of 
heat flow. The sample mass varied from 3‑10 ± 0.5 mg and 
it was placed in sealed aluminum pans. The coolant used 
was liquid nitrogen. The samples were scanned at 10°/min 
from 20° to 300°. 
X‑ray powder diffractometry studies
X‑ray powder diffractometry (XPRD) patterns for 
pioglitazone, Mβ‑CD, physical mixtures and inclusion 
complexes were traced employing X‑ray diffractometer 
(Bruker Axs D8 Advance, Germany) with scanning rate 
4°/min and voltage/current used was 40 kV/50 mA and 
the target/filter was copper.
Stability studies
The prepared selected formulation was stored at 40°C ± 
2°C/75% RH ± 5% RH in Newtronic Temperature/
Humidity Control Chamber QLH‑ 2004 for a period of Pandit, et al.: Pioglitazone cyclodextrin inclusion complexes
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6 months. The samples were withdrawn every month and 
were evaluated for drug content and in vitro dissolution 
studies. 
RESULTS AND DISCUSSION
Phase solubility studies
The phase solubility diagram for the complex formation 
between pioglitazone and β‑CD/Mβ‑CD/γ‑CD are 
presented in the Figure 1. The plots show that aqueous 
solubility of pioglitazone increases linearly as a function 
of cyclodextrin concentration up to 2.5 mM. It is clearly 
observed that the solubility diagram of pioglitazone in the 
presence of β‑CD/Mβ‑CD and γ‑CD can be classified as 
AL type according to Higuchi and Connors. As slope is less 
than 1 and the plot is AL type, 1:1 ratio of drug and the 
respective CD is selected for complexation. The apparent 
stability constants (KS) were calculated from the straight 
line portion of the phase solubility diagram [Table 1]. The 
cavity size of Mβ‑CD seems to be optimal for entrapment 
of pioglitazone molecules as it provides the greatest 
solubilization effect. Stability constants obtained for 
pioglitazone are in the rank order of methyl‑β > β > γ‑CD. 
The change in Gibb’s free energy (ΔG0) is the net energy 
available to do useful work and is a measure of the “free 
energy” [Table 2]. ΔG0 gives criteria for spontaneity at 
constant pressure and temperature.[14] If ΔG0 is negative, the 
process is spontaneous. As ΔG0 becomes more negative, the 
reaction becomes more favorable. In the present case, the 
reaction consists of the solubility of the drug in cyclodextrin 
solution. ΔG0 is related to the equilibrium constant of a 
reaction K, by the relation ΔG0 = −2.3.3RT log K where K 
is calculated from (S0/Ss). It was observed that ΔG0 values 
obtained were negative which increased with increasing CD 
concentration in all the different types of CDs evaluated 
in this study. This indicates that CD solutions offer a more 
favorable environment than water for pioglitazone.
Preparation of inclusion complexes
Preparation of  inclusion complexes by kneading method
Cyclodextrin complexes of pioglitazone were prepared using 
1:1 M ratio of drug and the corresponding CD’s (β‑CD, 
Mβ‑CD and γ‑CD) as indicated by phase solubility studies. 
The products formed were free flowing in nature and white 
in color. The prepared complexes subjected to solubility 
analysis showed a constant reading after 4 h studies. 
The solubility studies indicated that among the prepared 
complexes, Mβ‑CD complexes had maximum solubility 
(1.584 ± 0.053 mg/ml) and therefore selected for further 
evaluation.
Preparation of  inclusion complexes by spray drying method
Spray drying method represents one of the most commonly 
employed methods to produce the inclusion complexes 
starting from a solution. The mixture is passed to a fast 
elimination system to produce complexes having high 
efficiency.[15]
As per the solubility studies of kneaded complexes, Mβ‑CD 
was selected for preparation of drug complexes by spray 
drying method.
As pioglitazone is insoluble in water the same cannot be 
used as solvent. Precipitation must be controlled in order 
to avoid the particles blocking the atomizer or spray nozzle, 
hence clear solution is desirable.[16]
Ethanol‑acetone mixture in different ratios was used as 
solvent system for preparation of complexes based on 
solubility of drug and Mβ‑CD. 1:1 ratio was selected as it gave 
a clear solution whereas other ratios formed a turbid solution.
Figure 1: Phase solubility diagram of pioglitazone HCl
Table 1: Stability constants (Ks) and slope for 
pioglitazone‑CD complexes
Type of cyclodextrin Slope Stability constant (M−1)
Methyl β‑cyclodextrin
β‑cyclodextrin
γ‑cyclodextrin
0.331
0.2073
0.0337
2747.19
1452.03
359.06
Table 2: Gibbs free energy of pioglitazone‑CD 
complexes in water
Conc. of 
cyclodextrin (mM)
Gibbs free energy ‑ ΔtransG0/cal/mol−1
Mβ‑CD β‑CD γ‑CD
0.5
1
1.5
2.5
5
10
23.029
186.669
218.183
347.773
391.918
308.662
138.408
225.554
309.973
328.5194
354.926
497.496
50.591
77.101
87.105
93.967
135.441
187.934
mM, millimolar; Mβ‑CD, methyl β‑cyclodextrin; β‑CD is β‑cyclodextrin; γ‑CD is 
γ‑cyclodextrinPandit, et al.: Pioglitazone cyclodextrin inclusion complexes
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The process parameters for spray drying technique were 
optimized in preliminary studies. The various process 
parameters considered were inlet air temperature, outlet 
air temperature, feed rate, atomization air pressure and 
aspirator speed.
The inlet air temperature and outlet air temperature was 
optimized to 65° and 55°, respectively, based on boiling 
point of the solvents used and stability of the drug to get 
dry and stable product. 
The different feed rates i.e., 3, 5 and 7 ml/min were 
selected. It was found that higher the feed rate, lower was 
the yield. When the feed rate was kept at 2 ml/min the yield 
was decreased and the time taken for the process was long. 
Therefore, 3 ml/min was selected as optimum feed rate to 
get maximum yield of the complexes. 
Atomization air pressure and aspirator speed were 
optimized at 2.5 kg/cm2 and 30, respectively, so as to 
achieve good yield and decrease the time taken for the 
process.
The product formed was white in color and free flowing in 
nature. However, the yield was less compared to kneading 
method due to adherence of the product to the drying 
chamber and accumulation in scrubber. The product 
obtained by this method had uniform particles which in 
turn improves the solubility and thus dissolution rate of 
drug in complex form.
Solubility studies
Pioglitazone complexes were subjected to solubility 
studies in water and the results were shown in Table 3. It 
was observed kneaded Mβ‑CD complexes exhibited the 
solubility of 1.584 ± 0.053 mg/ml whereas kneaded γ‑CD 
and kneaded β‑CD complexes exhibited the solubility 
of 0.1448 ± 011 mg/ml and 0.425 ± 0.041 mg/ml, 
respectively. Based on this solubility data Mβ‑CD was 
selected for preparing drug complexes by spray drying 
technique in order to further enhance the solubility of 
pioglitazone.
Mβ‑CD cyclodextrin complex prepared by spray drying 
method showed a maximum increase in the solubility of 
2.29 ± 0.001 mg/ml. The complexes prepared by spray 
drying method showed a 32‑fold increase in solubility 
than the pure drug (0.0714 ± 0.0018 mg/ml) as shown 
in Figure 2.
In vitro dissolution studies
The prepared kneaded complexes of β‑CD, Mβ‑CD 
and γ‑CD along with Mβ‑CD complexes prepared by 
spray drying technique were subjected for dissolution 
studies. It was observed that spray‑dried complexes has 
shown the drug release of 84.66% in 60 min where as 
γ‑CD, β‑CD and Mβ‑CD‑kneaded complexes showed 
release of 34.71%, 41.64% and 51.13 % in 60 min. The 
enhanced dissolution rate of spray‑dried products might 
be attributed to decreased particle size, increased surface 
area and formation of uniform‑sized complexes. The 
dissolution profile obtained for inclusion complexes is 
shown in Figure 3.
Characterization studies such as FTIR, SEM, DSC and 
XRPD were further carried for drug‑MβCD kneaded and 
spray‑dried complexes, in order to determine formation 
of inclusion complex.
Fourier transforms infrared spectroscopy studies
The IR spectra of pure drug, physical mixtures of 
pioglitazone‑Mβ‑CD and complexes are shown in Figure 4. 
The IR spectrum of pioglitazone revealed the presence 
of peak at 3085.89 cm−1 due to N‑H stretching while 
peaks at 2927.74 and 2740.66 cm−1 is due to aliphatic C‑H 
stretching. Strong absorption peaks observed at 1743.53 
and 1689.53 cm−1 were assigned to drug carbonyl stretching 
vibration (C=O). A peak at 1612 cm−1 indicates the 
Figure 2: Solubility profile of complexes in water
Table 3: Solubility studies of the prepared complexes
Complexation technique *Solubility of pure drug (mg/ml) ± SD *Solubility of complexes (mg/ml) ± SD
γ‑CD β‑CD Mβ‑CD
Physical mixtures 0.0714 ± 0.0013 0.101 ± 0.0013 0.275 ± 0.0043 1.1425 ± 0.003
Kneading 0.0714 ± 0.0023 0.144 ± 0.0022 0.425 ± 0.0031 1.584 ± 0.0042
Spray drying 0.0714 ± 0.0018 ‑ ‑ 2.29 ± 0.001
SD‑standard deviation; γ‑CD is γ‑cyclodextrin; β‑CD is β‑cyclodextrin; Mβ‑CD is methyl β‑cyclodextrin. *Average of three determinationsPandit, et al.: Pioglitazone cyclodextrin inclusion complexes
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aromatic ring and a peak at 1238 cm−1 is due to C‑O Ar 
group. Mβ‑CD showed prominent peak at 3402.2 cm−1 due 
to O‑H stretching. Physical mixture of drug and Mβ‑CD 
shows summation of the spectra of the drug and Mβ‑CD, 
equivalent to the addition of the spectrum of cyclodextrin 
and drug. So presence of all these characteristic peaks 
of pioglitazone in physical mixture reveals that the drug 
remains intact and there is no interaction between drug and 
excipients. Whereas all peaks of pioglitazone were found 
to be smoothened in complexes indicating strong physical 
interaction of pioglitazone with Mβ‑CD. The peak of OH 
group of Mβ‑CD at 3402.2 cm−1 was shifted toward lower 
frequency due to intermolecular hydrogen bonding with 
pioglitazone in both kneaded and spray‑dried complexes.
The peak at 1635.52 cm−1 in IR spectra of Mβ‑CD due to 
water of crystallization, disappeared in both the inclusion 
complexes. The binary systems of pioglitazone‑Mβ‑CD 
did not show any new peaks, indicating no chemical bond 
formation in the complexes and formation of inclusion 
complex in solid state. Changes in the characteristic bands 
of pure drug confirm the existence of the complex as a 
new compound with different spectroscopic bands.
Scanning electron microscopy studies
SEM study indicated that pure drug particles were irregular 
in shape, whereas Mβ‑CD showed spherical particles. The 
physical mixture of the drug and Mβ‑CD shows that drug 
particle remains dispersed and physically adsorbed on the 
surface of the Mβ‑CD particles.
Following inclusion complexation of drug with Mβ‑CD 
by kneading and spray drying methods, Mβ‑CD showed 
loss of sphericity, smooth surface and reduced size of the 
particles. A drastic change in the morphology and shape of 
the drug particles was observed in the inclusion complex, it 
was no longer possible to differentiate the two components, 
drug‑Mβ‑CD complexes and Mβ‑CD. Hence changes 
in the particle shape and size, suggested an apparent 
interaction between drug and Mβ‑CD [Figure 5].
Differential scanning calorimetry studies
The DSC thermogram of pure drug, Mβ‑CD, physical 
mixtures and complexes are shown in Figure 6. The DSC 
thermogram of pure pioglitazone showed an endothermic 
peak at 201.9°, corresponding to its melting point. Peak at 
68.13° observed for Mβ‑CD thermogram corresponds to 
its dehydration process.
The thermogram of pioglitazone and Mβ‑CD (1:1) physical 
mixture showed two peaks. The peak at 63.13° is due to 
dehydration process of Mβ‑CD and peak at 196.9° is the 
shift of drug peak to a lower temperature, indicating that 
a true complex has not formed.
DSC can be used for the recognition of inclusion complexes. 
When guest molecules are embedded in CD cavities, their 
melting, boiling or sublimation points generally shift to 
a different temperature or disappear. The thermal curve 
of pioglitazone and Mβ‑CD (1:1) complex prepared by 
kneading method showed only one peak at 181.1° and those 
prepared by spray dried showed a peak at 154.1° which is 
due to dehydration process of Mβ‑CD. The disappearance 
of endothermic peak due to pioglitazone with these systems 
indicated the formation of true complex of pioglitazone 
and Mβ‑CD at 1:1 M ratio.
X‑ray powder diffraction studies
The X‑ray diffraction patterns of pure drug, Mβ‑CD and 
complexes are shown in Figure 7. In the X‑ray diffractogram 
of pioglitazone it is possible to observe several sharp peaks 
in the range from 0 to 30 (degrees 2θ) suggesting that the 
drug is present in a crystalline form. On the other hand, the 
Figure 3: In vitro dissolution studies of CD complexes
Figure 4: IR spectra of (a) pure pioglitazone (b) physical mixture of 
pioglitazone and pure Mβ‑CD (c) kneaded complexes (d) spray‑dried 
complexesPandit, et al.: Pioglitazone cyclodextrin inclusion complexes
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XRPD pattern of Mβ‑CD confirms its amorphous form. 
In the case of the physical mixtures the XRPD spectrum is 
simply the superposition of those of the single components. 
A decrease in the peak intensity, crystallinity loss, was 
observed in the physical mixtures diffractogram, probably 
due to the amorphous character of the cyclodextrin.
XRPD is a useful method for the detection of cyclodextrin 
complexation in powder or microcrystalline states. The 
diffraction pattern of the complex is supposed to be clearly 
distinct from that of drug and CD.
Crystallinity is determined by comparing representative 
peak heights in the diffraction patterns. In both kneaded 
and spray‑dried complexes some characteristic pioglitazone 
peaks were still detectable but with lower intensity 
indicating that the crystallinity of the drug was reduced 
to a great extent and conversion into an amorphous state. 
No new peaks could be observed, suggesting the absence 
of interaction between the drug and the carrier.
Stability studies
The selected formulation was subjected to accelerated 
stability studies as per ICH guidelines for 6 months. The 
samples were tested for any changes in physical appearance, 
drug content and in vitro dissolution profile at monthly 
intervals. The results showed that there was no significant 
difference (P>0.05) in the drug content and dissolution 
behavior of the selected formulation. 
CONCLUSIONS
In the present work an attempt has been made to achieve 
Figure 5: Scanning electron microscopy of (a) pure pioglitazone 
(b) pure Mβ‑CD (c) physical mixtures (d) kneaded complexes 
(e) spray‑dried complexes
Figure 6: DSC of (a) pure pioglitazone (b) pure Mβ‑CD (c) physical 
mixtures (d) pioglitazone kneaded complexes (e) pioglitazone 
spray‑dried complexes
Figure 7: XRPD of (a) pure pioglitazone (b) pure Mβ‑CD (c) physical 
mixtures (d) pioglitazone kneaded complexes (e) pioglitazone 
spray‑dried complexesPandit, et al.: Pioglitazone cyclodextrin inclusion complexes
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faster onset of hypoglycemic action with pioglitazone by 
enhancement of solubility through complexation with 
CDs. Phase solubility studies indicated the formation of 
complexes in 1:1 M ratio, forming highly stable inclusion 
complex with methyl β‑CD followed by β‑CD and 
γ‑CD. Pioglitazone–Mβ‑CD systems allowed a marked 
improvement of the initial drug water solubility. In 
particular, an increase of about 22 times was obtained 
for kneaded product and about 32 times for spray‑dried 
product. FTIR, SEM, DSC and XRPD studies showed that 
complexes can be prepared by kneading and spray‑drying 
methods demonstrating that spray drying can be efficient 
method for inclusion complex formation between 
pioglitazone and Mβ‑CD.
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